Zenas BioPharma, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
ZBIO$28.26+9.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Early development programs
Early development programs
| · | ZB022, an oral, brain-penetrant, TYK2-JH2 inhibitor |
| o | IND enabling studies ongoing: Zenas expects to initiate a Phase 1 clinical study in 2027. |
| · | ZB014, a half-life extended, inhibitor of B cell function targeting CD19 and FcγRIIb monoclonal antibody (mAb) |
| o | IND enabling studies ongoing: Developed using half-life extension technology for mAbs, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule. Zenas expects to advance the program into Phase 1 clinical development in 2027. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.